|
Pioneer and World-Acclaimed Leader in Field of Umbilical Cord Blood,
Cord Blood Banking and Stem Cell Separation and Treatment, to Bring
Development Activities to Scientific and Major Pharma Communities
HAIFA, Israel--(BUSINESS WIRE)--Nov. 9, 2005--Pluristem Life Systems,
Inc. (OTC BB: PLRS - News; the "Company"), a biotechnology company
dedicated to the expansion of stem cells from umbilical cord blood to
address a myriad of fatal illnesses, today announced that Arnon Nagler,
M.D., M.S.c. has joined the Company's Scientific Advisory Board.
Professor Nagler
is a pioneer and world renowned leader in the field of human umbilical
cord blood. His first publication addressing stem cell separation and
purification from human umbilical cord blood was published in 1994. He
established the first cord blood bank in Israel in 1994 and performed
the first related and unrelated cord blood transplants in Israel in 1994
and 1996 respectively. Professor Nagler, additionally, was part of the
team that performed the first gene therapy cord blood transplantation in
Israel in a child. -
Professor Nagler is founding member of NetCord (the European network of
cord blood therapy) and a formal cord blood inspection of the
FACHT/NetCord organization. Professor Nagler's cord blood bank at Sheba
Medical Center was recently accredited by the NMDP.
Among Dr. Nagler's myriad of awards, his most recent include the Best
Abstract Award from the American Society of Bone and Marrow
Transplantation (ABSMT) in February 2004 and the Best Abstract from the
National Marrow Donor Program Meeting in October, 2004. Professor.
Nagler has received over forty grants from government, research
associations, foundations and pharmaceutical companies for his ongoing
research. He holds over forty patents and trademarks, has been the lead
investigator on over fifteen clinical trials, is an international
sought-after lecturer, and widely published.
His tenure with leading edge biotech and pharmaceutical companies
included his role as Technical Leader and Medical Advisor to Gamida
Cell. Dr. Nagler is a Professor Medicine at Tel-Aviv University,
Director of Hematology at Chaim Sheba Medical Center, Tel-Hashomer and
is also Director of Bone Marrow Transplantation and the Cord Blood Bank.
Dr. Nagler served as a fellow in medicine/hematology at Stanford
University School of Medicine from 1986 until 1989 and is a member of
the American Society of Hematology.
"Pluristem's technology holds great potential in the field of tissue
engineering and the expansion of umbilical cord blood stem cells. I hope
to assist them in exploring a number of opportunities in the scientific
realm and thoroughly analyze the technology and bring it to its full
potential," stated Professor Arnon Nagler.
"Professor Nagler's acceptance of this appointment is a tremendous honor
to Pluristem. His ground-breaking and ongoing work in the field of human
umbilical cord blood along with his unbreakable ties to the scientific
and pharmaceutical communities are of great value to us as we move our
science to the development stages and on to clinical trials," stated
Zami Aberman, CEO.
"Professor Nagler's appointment represents one of the strongest
endorsements of our technology and the abilities of the U.S. patented
PluriX(TM) bioreactor that exists," Aberman concluded.
About Pluristem
Pluristem is a biopharmaceutical company developing stem cell products
for cell regenerative therapy. Pluristem's platform for expanding stem
cells offers breakthrough technology and multiple product opportunities
in many therapeutic areas. Pluristem has exclusive rights to the
Plurix(TM) cell expansion system under a licensing agreement with
Technion Institute of Technology and the Weisman Institute of Science.
For more information, visit the Company's website at: www.pluristem.com.
Safe Harbor Statement
This press release contains statements, which may constitute
"forward-looking statements". Those statements include statements
regarding the intent, belief or current expectations of Pluristem Life
Systems, Inc., and members of our management as well as the assumptions
on which such statements are based. Forward-looking statements in this
release include statements that include Pluristem's technology holds
great potential in the field of tissue engineering and the expansion of
umbilical cord blood stem cells; that Professor's Nagler's contacts and
experience are of great value to us as we move our science to the
development stages and on to clinical trials; and that our platform for
expanding stem cells offers breakthrough technology and multiple product
opportunities in many therapeutic areas. Factors which may significantly
change or prevent our forward looking statements from fruition include
that we may be unsuccessful in developing any products; Professor
Nagler's may be unable to make contacts for us or his contacts may not
be interested in our company; Professor Nagler may cease being on our
advisory board before being able to assist us; that our patents are not
sufficient to protect essential aspects of our technology; that
competitors may invent better technology; that our products may not work
as well as hoped or worse, that our products may harm recipients; and
that we may not be able raise funds for development or working capital
when we require it. As well, our products may never develop into useful
products and even if they do, they may not be approved for sale to the
public. For further risk factors see the Company's latest 10-KSB filed
with the SEC.
Contact:
Investor:
DeMonte Associates
Cynthia DeMonte, 212-605-0525
cdemonte@aol.com
--------------------------------------------------------------------------------
Source: Pluristem Life Systems, Inc.
|
